BackQomolangma Acquisition - Tradeable Rights - Nov 2022 Overview

Qomolangma Acquisition - Tradeable Rights - Nov 2022 Total Liabilities

Qomolangma Acquisition - Tradeable Rights - Nov 2022's total liabilities is $5.1M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$5.14M
58.82% YoYΔ $1.90M vs prior year quarter

Peer average / median

Loading

Qomolangma Acquisition - Tradeable Rights - Nov 2022 Total Liabilities History

Loading

Qomolangma Acquisition - Tradeable Rights - Nov 2022 vs. peers: Total Liabilities Comparison

Loading

Qomolangma Acquisition - Tradeable Rights - Nov 2022 Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Qomolangma Acquisition - Tradeable Rights - Nov 2022 (QOMOR) FAQ

As of the most recent data (March 2024), QOMOR shows a total liabilities of $5.1M. That compares with $3.2M in the prior-year period — up 58.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, QOMOR's total liabilities is now $5.1M (was $3.2M) — a 58.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Qomolangma Acquisition - Tradeable Rights - Nov 2022 is outperforming or lagging.

Tracking QOMOR's total liabilities over time shows whether Qomolangma Acquisition - Tradeable Rights - Nov 2022 is scaling, shrinking, or reshaping that part of the business. The current reading is $5.1M That compares with $3.2M in the prior-year period — up 58.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Qomolangma Acquisition - Tradeable Rights - Nov 2022's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $5.1M) with ownership activity and broader fundamentals.